POMC and neoplasm: Together, these findings suggest a potential difference in effect between mifepristone and relacorilant, in which relacorilant-induced increased SSTR2 expression on the tumor can increase the efficacy of endogenous and exogenous somatostatin on ACTH secretion and tumor proliferation.